Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Researcher

Bram Van Den Eeckhout

Awards & Distinctions

12 Results

2024

In-depth analysis of the HIV reservoir confirms effectiveness and safety of dolutegravir/lamivudine in a phase 4 randomized controlled switch trial (RUMBA)

Marie-Angélique De ScheerderSophie DegrooteMareva DelporteMaja KiselinovaWim TrypsteenLara VinckeEvelien De SmetBram Van Den EeckhoutLoic SchrooyenMaxime Verschoore et al.

A1 Journal Article in JOURNAL OF INFECTIOUS DISEASES

2023

A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state

Sandra Van LintAlexander Van ParysBram Van Den EeckhoutNiels VandammeStephane PlaisanceAnnick VerheeDominiek CatteeuwElke RoggeJennifer De GeestNele Vanderroost et al.

A1 Journal Article in MOLECULAR CANCER

Rethinking IL-1 antagonism in respiratory viral infections : a role for IL-1 signaling in the development of antiviral T cell immunity

Bram Van Den EeckhoutMarlies BallegeerJozefien De ClercqElianne BurgXavier SaelensLinos VandekerckhoveSarah Gerlo

A1 Journal Article in INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

2021

Development of IL-1β AcTakines : towards new adjuvants in vaccination strategies

Bram Van Den EeckhoutSarah GerloJan Tavernier

Interleukin-1 as innate mediator of T cell immunity

Bram Van Den EeckhoutJan TavernierSarah Gerlo

A1 Journal Article in FRONTIERS IN IMMUNOLOGY

Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication

Bram Van Den EeckhoutLeander HuygheSandra Van LintElianne BurgStéphane PlaisanceFrank PeelmanAnje CauwelsGilles UzéNiko KleySarah Gerlo et al.

A1 Journal Article in JOURNAL FOR IMMUNOTHERAPY OF CANCER

Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE

Anje CauwelsSandra Van LintElke RoggeAnnick VerheeBram Van Den EeckhoutShengru PangMarco PrinzNiko KleyGilles UzeJan Tavernier

A1 Journal Article in SCIENTIFIC REPORTS

2020

Selected IL-1 activity on CD8+ T cells allows for safe enhancement of cellular immune responses

Bram Van Den EeckhoutLien Van HoeckeElianne BurgSandra Van LintFrank PeelmanNiko KleyGilles UzéXavier SaelensJan TavernierSarah Gerlo

Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant

Bram Van Den EeckhoutLien Van HoeckeElianne BurgSandra Van LintFrank PeelmanNiko KleyGilles UzéXavier SaelensJan TavernierSarah Gerlo

A1 Journal Article in NPJ VACCINES

2019

Towards the use of interleukin-1β as vaccine adjuvant

Bram Van Den EeckhoutLien Van HoeckeElianne BurgSandra Van LintFrank PeelmanXavier SaelensJan TavernierSarah Gerlo

2018

IL-1β AcTaleukins : towards potent yet safe adjuvants for tumor vaccination

Bram Van Den EeckhoutElianne BurgAnje CauwelsFrank PeelmanSandra Van LintJan TavernierSarah Gerlo

2017

IL-1β AcTaleukins : towards potent yet safe adjuvants for tumor vaccination

Bram Van Den EeckhoutElianne BurgAnje CauwelsFrank PeelmanSandra Van LintJan TavernierSarah Gerlo